Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
暂无分享,去创建一个
[1] K. Shimada,et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. , 2014, JAMA.
[2] S. Jacob,et al. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? , 2007, Interactive cardiovascular and thoracic surgery.
[3] M. Roncaglioni. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.
[4] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.
[5] F. Ferris. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992, JAMA.
[6] Aspirin for primary prevention of cardiovascular disease? , 2010, Evidence Based Medicine.
[7] G. Tognoni,et al. Association of aspirin use with major bleeding in patients with and without diabetes. , 2012, JAMA.
[8] C Warlow,et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[9] E. Whitlock,et al. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.
[10] D. Buist,et al. Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.
[11] P. Rothwell,et al. Eff ect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies , 2007 .
[12] D. Buist,et al. Aspirin Use for the Prevention of Colorectal Cancer , 2015 .
[13] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[14] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.
[15] P. Macfarlane,et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.
[16] T. Morimoto,et al. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients with Type 2 Diabetes: A Randomized Controlled Trial , 2009 .
[17] A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women , 2005 .
[18] J. Price,et al. Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial , 2011 .
[19] A. Algra,et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.
[20] Jason C. Fish,et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[21] Kathryn A. Morbitzer,et al. Aspirin for Primary Prevention of Cardiovascular Disease Events , 2012, Pharmacotherapy.
[22] Evelyn Whitlock,et al. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.
[23] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[24] R. Doll,et al. Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.
[25] Seemant Chaturvedi,et al. Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.
[26] Melonie P. Heron. Deaths: Leading Causes for 2011. , 2015, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[27] Melonie P. Heron,et al. Deaths: leading causes for 2007. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[28] L. Perdue,et al. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. , 2022, JAMA.
[29] Á. Lanas,et al. Time Trends and Impact of Upper and Lower Gastrointestinal Bleeding and Perforation in Clinical Practice , 2009, The American Journal of Gastroenterology.
[30] S. Hernández-Díaz,et al. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications , 2006, BMC Medicine.
[31] M. Fornage,et al. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.
[32] D. DeMets,et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[33] G. Moneta. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2009 .
[34] E. Whitlock,et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms , 2015 .
[35] J. Wallace. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? , 2008, Physiological reviews.
[36] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[37] P. Sandercock,et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. , 2010, JAMA.
[38] N. Cook,et al. Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial , 2013, Annals of Internal Medicine.
[39] P. Rothwell,et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.
[40] A. Mainous,et al. Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012 , 2014, Journal of the American Heart Association.
[41] E. Whitlock,et al. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.
[42] G. de Gaetano. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. , 2001, Lancet.
[43] P. Wilson,et al. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation , 2010, Circulation.